Drug intelligence / Profile preview

oxyntomodulin

Development stage
Phase 1
Lead developer
OPKO Health
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

Oxyntomodulin is a naturally occurring 37-amino acid peptide hormone secreted by enteroendocrine L-cells of the gut in response to food intake. It acts as a dual agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), combining effects of GLP-1 and glucagon. This dual action results in reduced appetite, increased satiety, enhanced energy expenditure, and weight loss. Oxyntomodulin has been shown to lower body weight more effectively than selective GLP-1R agonists alone and can improve glucose tolerance in patients with type 2 diabetes mellitus by counterbalancing the hyperglycemic effect of GCGR activation with GLP-1R-mediated glucose lowering. Its mechanism involves central effects on appetite regulation via hypothalamic pathways as well as peripheral metabolic actions. Clinical studies are ongoing for its use in obesity and diabetes.

Other names
OXM
02

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on oxyntomodulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxyntomodulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call